Does the media favor JNJ or NVO?

In the previous week, Johnson & Johnson had 78 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 104 mentions for Johnson & Johnson and 26 mentions for Novo Nordisk A/S. Johnson & Johnson's average media sentiment score of 1.16 beat Novo Nordisk A/S's score of 0.60 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 78 Very Positive mention(s) 6 Positive mention(s) 14 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Novo Nordisk A/S 13 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, MRK or NVO?

Merck & Co., Inc. has higher revenue and earnings than Novo Nordisk A/S. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Merck & Co., Inc. $65.01B 5.71 $18.25B $1.25 120.30 Novo Nordisk A/S $46.80B 4.45 $15.51B $4.09 11.39

Does the media refer more to MRK or NVO?

In the previous week, Merck & Co., Inc. had 7 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 33 mentions for Merck & Co., Inc. and 26 mentions for Novo Nordisk A/S. Merck & Co., Inc.'s average media sentiment score of 1.29 beat Novo Nordisk A/S's score of 0.60 indicating that Merck & Co., Inc. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merck & Co., Inc. 27 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Novo Nordisk A/S 13 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Is NVS or NVO more profitable?

Novo Nordisk A/S has a net margin of 35.36% compared to Novartis' net margin of 23.29%. Novo Nordisk A/S's return on equity of 61.20% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novartis 23.29% 38.56% 14.47% Novo Nordisk A/S 35.36% 61.20% 21.49%

Does the media favor NVS or NVO?

In the previous week, Novartis had 18 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 44 mentions for Novartis and 26 mentions for Novo Nordisk A/S. Novo Nordisk A/S's average media sentiment score of 0.60 beat Novartis' score of 0.12 indicating that Novo Nordisk A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 13 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 16 Negative mention(s) 0 Very Negative mention(s) Neutral Novo Nordisk A/S 13 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AZN or NVO?

In the previous week, Novo Nordisk A/S had 13 more articles in the media than Astrazeneca. MarketBeat recorded 26 mentions for Novo Nordisk A/S and 13 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 0.82 beat Novo Nordisk A/S's score of 0.60 indicating that Astrazeneca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Novo Nordisk A/S 13 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, NVO or PFE?

Novo Nordisk A/S has higher earnings, but lower revenue than Pfizer. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $46.80B 4.45 $15.51B $4.09 11.39 Pfizer $62.58B 2.59 $7.77B $0.76 37.39

Is NVO or PFE more profitable?

Novo Nordisk A/S has a net margin of 35.36% compared to Pfizer's net margin of 6.80%. Novo Nordisk A/S's return on equity of 61.20% beat Pfizer's return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 35.36% 61.20% 21.49% Pfizer 6.80% 19.63% 8.46%

Does the media prefer NVO or PFE?

In the previous week, Pfizer had 58 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 84 mentions for Pfizer and 26 mentions for Novo Nordisk A/S. Pfizer's average media sentiment score of 0.84 beat Novo Nordisk A/S's score of 0.60 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 13 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Pfizer 37 Very Positive mention(s) 22 Positive mention(s) 18 Neutral mention(s) 2 Negative mention(s) 4 Very Negative mention(s) Positive

Novo Nordisk A/S (NVO) Competitors

$46.59 -0.01 (-0.02%)

As of 09/4/2026 03:58 PM Eastern

Compare

NVO vs. JNJ, MRK, NVS, AZN, and PFE

Should you buy Novo Nordisk A/S stock or one of its competitors? Novo Nordisk A/S's main competitors and comparable companies include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Novartis (NVS), Astrazeneca (AZN), and Pfizer (PFE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Novo Nordisk A/S compare to Johnson & Johnson?

Johnson & Johnson (NYSE:JNJ) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Johnson & Johnson has higher revenue and earnings than Novo Nordisk A/S. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	7.04	$26.80B	$8.63	31.88
Novo Nordisk A/S	$46.80B	4.45	$15.51B	$4.09	11.39

Johnson & Johnson has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Novo Nordisk A/S has a net margin of 35.36% compared to Johnson & Johnson's net margin of 21.48%. Novo Nordisk A/S's return on equity of 61.20% beat Johnson & Johnson's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.48%	32.42%	13.35%
Novo Nordisk A/S	35.36%	61.20%	21.49%

Johnson & Johnson presently has a consensus target price of $272.83, suggesting a potential downside of 0.83%. Novo Nordisk A/S has a consensus target price of $64.94, suggesting a potential upside of 39.38%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80
Novo Nordisk A/S	1 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.16

In the previous week, Johnson & Johnson had 78 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 104 mentions for Johnson & Johnson and 26 mentions for Novo Nordisk A/S. Johnson & Johnson's average media sentiment score of 1.16 beat Novo Nordisk A/S's score of 0.60 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	78 Very Positive mention(s)	6 Positive mention(s)	14 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	13 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 1.9%. Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 1.8%. Johnson & Johnson pays out 62.1% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 64 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Johnson & Johnson beats Novo Nordisk A/S on 14 of the 20 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Merck & Co., Inc.?

Merck & Co., Inc. (NYSE:MRK) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 2.3%. Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 1.8%. Merck & Co., Inc. pays out 272.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend. Merck & Co., Inc. has raised its dividend for 14 consecutive years. Merck & Co., Inc. is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

76.1% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 0.2% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Merck & Co., Inc. has higher revenue and earnings than Novo Nordisk A/S. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merck & Co., Inc.	$65.01B	5.71	$18.25B	$1.25	120.30
Novo Nordisk A/S	$46.80B	4.45	$15.51B	$4.09	11.39

Merck & Co., Inc. has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Novo Nordisk A/S has a net margin of 35.36% compared to Merck & Co., Inc.'s net margin of 4.77%. Novo Nordisk A/S's return on equity of 61.20% beat Merck & Co., Inc.'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merck & Co., Inc.	4.77%	16.73%	6.13%
Novo Nordisk A/S	35.36%	61.20%	21.49%

Merck & Co., Inc. presently has a consensus target price of $148.60, suggesting a potential downside of 1.18%. Novo Nordisk A/S has a consensus target price of $64.94, suggesting a potential upside of 39.38%. Given Novo Nordisk A/S's higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merck & Co., Inc.	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.65
Novo Nordisk A/S	1 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.16

In the previous week, Merck & Co., Inc. had 7 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 33 mentions for Merck & Co., Inc. and 26 mentions for Novo Nordisk A/S. Merck & Co., Inc.'s average media sentiment score of 1.29 beat Novo Nordisk A/S's score of 0.60 indicating that Merck & Co., Inc. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merck & Co., Inc.	27 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Novo Nordisk A/S	13 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Merck & Co., Inc. beats Novo Nordisk A/S on 12 of the 19 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Novartis?

Novartis (NYSE:NVS) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 1.9%. Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 1.8%. Novartis pays out 46.5% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novo Nordisk A/S has lower revenue, but higher earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.60	$13.98B	$6.63	24.13
Novo Nordisk A/S	$46.80B	4.45	$15.51B	$4.09	11.39

Novo Nordisk A/S has a net margin of 35.36% compared to Novartis' net margin of 23.29%. Novo Nordisk A/S's return on equity of 61.20% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	23.29%	38.56%	14.47%
Novo Nordisk A/S	35.36%	61.20%	21.49%

Novartis has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

In the previous week, Novartis had 18 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 44 mentions for Novartis and 26 mentions for Novo Nordisk A/S. Novo Nordisk A/S's average media sentiment score of 0.60 beat Novartis' score of 0.12 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	13 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	16 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novo Nordisk A/S	13 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Novartis presently has a consensus price target of $141.20, suggesting a potential downside of 11.72%. Novo Nordisk A/S has a consensus price target of $64.94, suggesting a potential upside of 39.38%. Given Novo Nordisk A/S's higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Novo Nordisk A/S	1 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.16

13.1% of Novartis shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Novartis and Novo Nordisk A/S tied by winning 9 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Astrazeneca currently has a consensus price target of $206.67, indicating a potential upside of 27.09%. Novo Nordisk A/S has a consensus price target of $64.94, indicating a potential upside of 39.38%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Novo Nordisk A/S	1 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.16

Astrazeneca has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Novo Nordisk A/S has a net margin of 35.36% compared to Astrazeneca's net margin of 17.02%. Novo Nordisk A/S's return on equity of 61.20% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
Novo Nordisk A/S	35.36%	61.20%	21.49%

In the previous week, Novo Nordisk A/S had 13 more articles in the media than Astrazeneca. MarketBeat recorded 26 mentions for Novo Nordisk A/S and 13 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 0.82 beat Novo Nordisk A/S's score of 0.60 indicating that Astrazeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Novo Nordisk A/S	13 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Novo Nordisk A/S has lower revenue, but higher earnings than Astrazeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.29	$10.23B	$6.69	24.31
Novo Nordisk A/S	$46.80B	4.45	$15.51B	$4.09	11.39

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.7%. Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 1.8%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Novo Nordisk A/S beats Astrazeneca on 10 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Pfizer?

Novo Nordisk A/S (NYSE:NVO) and Pfizer (NYSE:PFE) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Novo Nordisk A/S has higher earnings, but lower revenue than Pfizer. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.45	$15.51B	$4.09	11.39
Pfizer	$62.58B	2.59	$7.77B	$0.76	37.39

Novo Nordisk A/S currently has a consensus target price of $64.94, suggesting a potential upside of 39.38%. Pfizer has a consensus target price of $28.28, suggesting a potential downside of 0.50%. Given Novo Nordisk A/S's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.16
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19

Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 1.8%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.1%. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Novo Nordisk A/S has a net margin of 35.36% compared to Pfizer's net margin of 6.80%. Novo Nordisk A/S's return on equity of 61.20% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.36%	61.20%	21.49%
Pfizer	6.80%	19.63%	8.46%

In the previous week, Pfizer had 58 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 84 mentions for Pfizer and 26 mentions for Novo Nordisk A/S. Pfizer's average media sentiment score of 0.84 beat Novo Nordisk A/S's score of 0.60 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	13 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	37 Very Positive mention(s)	22 Positive mention(s)	18 Neutral mention(s)	2 Negative mention(s)	4 Very Negative mention(s)	Positive

Novo Nordisk A/S has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Comparatively, 0.6% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Pfizer beats Novo Nordisk A/S on 10 of the 19 factors compared between the two stocks.

Get Novo Nordisk A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVO vs. The Competition

Export

Metric	Novo Nordisk A/S	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$208.07B	$12.24B	$7.25B	$23.66B
Dividend Yield	1.75%	2.59%	2.54%	3.73%
P/E Ratio	11.39	651.70	212.67	25.22
Price / Sales	4.45	756.07	624.55	20.85
Price / Cash	9.94	15.18	28.92	19.95
Price / Book	7.08	11.09	11.01	4.83
Net Income	$15.51B	$2.83B	$3.49B	$1.07B
7 Day Performance	2.76%	4.42%	1.63%	0.43%
1 Month Performance	-1.30%	6.88%	4.42%	-0.78%
1 Year Performance	-15.52%	10.00%	24.21%	12.82%

Novo Nordisk A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVO Novo Nordisk A/S	4.112 of 5 stars	$46.59 0.0%	$64.94 +39.4%	-15.5%	$208.07B	$46.80B	11.39	69,505	Trending News
JNJ Johnson & Johnson	4.5961 of 5 stars	$274.86 +1.4%	$272.83 -0.7%	+54.4%	$662.69B	$94.19B	31.86	138,200	Positive News Insider Trade
MRK Merck & Co., Inc.	4.5535 of 5 stars	$150.27 +0.3%	$147.60 -1.8%	+77.8%	$370.86B	$66.57B	120.26	75,000	Positive News Analyst Forecast
NVS Novartis	2.7709 of 5 stars	$161.63 +0.2%	$141.20 -12.6%	+23.3%	$307.77B	$56.69B	24.33	75,267
AZN Astrazeneca	4.7167 of 5 stars	$161.98 -0.3%	$206.67 +27.6%	N/A	$251.01B	$58.74B	24.19	96,100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NVO) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Competitors

NVO vs. JNJ, MRK, NVS, AZN, and PFE

How does Novo Nordisk A/S compare to Johnson & Johnson?

Summary

How does Novo Nordisk A/S compare to Merck & Co., Inc.?

Summary

How does Novo Nordisk A/S compare to Novartis?

Summary

How does Novo Nordisk A/S compare to Astrazeneca?

Summary

How does Novo Nordisk A/S compare to Pfizer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novo Nordisk A/S (NVO) Competitors

NVO vs. JNJ, MRK, NVS, AZN, and PFE

How does Novo Nordisk A/S compare to Johnson & Johnson?

Which has preferable earnings & valuation, JNJ or NVO?

Which has more risk & volatility, JNJ or NVO?

Is JNJ or NVO more profitable?

Do analysts prefer JNJ or NVO?

Does the media favor JNJ or NVO?

Do insiders and institutionals hold more shares of JNJ or NVO?

Is JNJ or NVO a better dividend stock?

Summary

How does Novo Nordisk A/S compare to Merck & Co., Inc.?

Is MRK or NVO a better dividend stock?

Do insiders & institutionals believe in MRK or NVO?

Which has better earnings and valuation, MRK or NVO?

Which has more risk and volatility, MRK or NVO?

Is MRK or NVO more profitable?

Do analysts rate MRK or NVO?

Does the media refer more to MRK or NVO?

Summary

How does Novo Nordisk A/S compare to Novartis?

Is NVS or NVO a better dividend stock?

Which has higher valuation & earnings, NVS or NVO?

Is NVS or NVO more profitable?

Which has more volatility & risk, NVS or NVO?

Does the media favor NVS or NVO?

Do analysts recommend NVS or NVO?

Do insiders and institutionals believe in NVS or NVO?

Summary

How does Novo Nordisk A/S compare to Astrazeneca?

Do analysts rate AZN or NVO?

Which has more risk & volatility, AZN or NVO?

Is AZN or NVO more profitable?

Does the media favor AZN or NVO?

Which has stronger valuation & earnings, AZN or NVO?

Do institutionals & insiders have more ownership in AZN or NVO?

Is AZN or NVO a better dividend stock?

Summary

How does Novo Nordisk A/S compare to Pfizer?

Which has preferable earnings & valuation, NVO or PFE?

Do analysts prefer NVO or PFE?

Is NVO or PFE a better dividend stock?

Is NVO or PFE more profitable?

Does the media prefer NVO or PFE?

Which has more volatility & risk, NVO or PFE?

Do institutionals & insiders believe in NVO or PFE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools